Elutia (ELUT) Gross Margin (2019 - 2026)

Elutia (ELUT) posted Gross Margin of 57.87% for Q1 2026, down 1.1% sequentially from 58.51% in Q4 2025, and up 1104.0% YoY from 4.81% in Q1 2025.

Elutia (ELUT) Gross Margin (2019 - 2026) Analysis & Trends

Elutia has reported Gross Margin for 8 years, with the latest figure at 57.87% in Q1 2026.

Quarterly Gross Margin rose 1104.0% year-over-year to 57.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 54.02% (up 762.0% YoY) and the FY2025 annual result came in at 53.66%, up 724.0% from the prior year.
Gross Margin retreated to 57.87% in Q1 2026 per ELUT's latest filing, from 58.51% in the prior quarter.
Over five years, Gross Margin peaked at 58.51% in Q4 2025 and troughed at 36.19% in Q4 2023.
A 5-year average of 47.15% and a median of 46.83% in 2025 frame the typical range for Gross Margin.
The widest YoY moves for Gross Margin: up 1813 bps in 2022, down 1188 bps in 2022.
Over 5 years, Gross Margin stood at 46.55% in 2022, then declined by 22 bps to 36.19% in 2023, then climbed by 30 bps to 46.95% in 2024, then grew by 25 bps to 58.51% in 2025, then slipped by 1 bps to 57.87% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 57.87%, 58.51%, and 55.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	57.71%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	68.27%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	65.35%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	77.46%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	47.38%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	45.84%
10	Elutia	39.87 Mn	19.98 Mn	1.45 Mn	59.62%

Download Data